Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 2/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348652 | 0.73 | BACE1 (0.41) | BACE1 | |
| SCHEMBL3355569 | 0.71 | BACE1 (0.42) | MEN1KMT2ABACE1 | |
| SCHEMBL23385216 | 0.71 | CYP2C9 (0.50) | NTRK1MAPK8METAP2CES2CES1 | |
| SCHEMBL4041675 | 0.70 | BACE1 (0.50) | BACE1 | |
| SCHEMBL4244530 | 0.68 | MAPK8 (0.38) | EPHX1NTRK1MAPK8MEN1KMT2A | |
| SCHEMBL6647479 | 0.66 | BACE1 (0.46) | BACE1 | |
| SCHEMBL3351919 | 0.66 | BACE1 (0.46) | BACE1 | |
| SCHEMBL23384780 | 0.62 | CYP2C9 (0.44) | METAP2IDO1 | |
| SCHEMBL19438593 | 0.62 | CAPN1 (0.46) | EPHX1MAPK8CES2CES1IDO1 | |
| SCHEMBL319124 | 0.61 | IDO1 (0.42) | GSK3BBACE1CES2CES1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | PFIZER INC. | 2008-06-05 | — | — | US | claimed |
| EP-1794114-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032999-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | PFIZER INC. | 2008-06-05 | — | — | US | disclosed |
| EP-1794114-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032999-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | HNMT, PNMT, BHMT | BCAT2 764/4885EPHX1 77/4885NTRK1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.